

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Advisory Committee on Minority Health

**AGENCY:** Office of Minority Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice of meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the Advisory Committee on Minority Health (ACMH) will hold a meeting conducted as a telephone conference call. This call will be open to the public. Preregistration is required for both public participation and comment. Any individual who wishes to participate in the call should email [OMH-ACMH@hhs.gov](mailto:OMH-ACMH@hhs.gov) by June 18, 2018. Instructions regarding participating in the call and how to provide verbal public comments will be given at the time of preregistration.

Information about the meeting is available from the designated contact and will be posted on the website for the Office of Minority Health (OMH), [www.minorityhealth.hhs.gov](http://www.minorityhealth.hhs.gov). Information about ACMH activities can be found on the OMH website under the heading *About OMH*.

**DATES:** The conference call will be held on June 19, 2018, 1:00 p.m.–3:00 p.m. ET.

**ADDRESSES:** Instructions regarding participating in the call will be given at the time of preregistration.

**FOR FURTHER INFORMATION CONTACT:** Dr. Minh Wendt, Designated Federal Officer, Advisory Committee on Minority Health, Office of Minority Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Suite 600, Rockville, Maryland 20852. Phone: 240-453-8222; fax: 240-453-8223; email [OMH-ACMH@hhs.gov](mailto:OMH-ACMH@hhs.gov).

**SUPPLEMENTARY INFORMATION:** In accordance with Public Law 105-392, the ACMH was established to provide advice to the Deputy Assistant Secretary for Minority Health on improving the health of each racial and ethnic minority group and on the development of goals and specific program activities of the OMH.

The topics to be discussed during the teleconference include finalizing recommendations regarding creating a culturally sensitive system of care related to opioid misuse, discussing recommendations on the topic of serious mental illness, and discussing

the agenda for the next meeting. The recommendations will be given to the Deputy Assistant Secretary for Minority Health.

This call will be limited to 125 participants. The OMH will make every effort to accommodate persons with special needs. Individuals who have special needs for which special accommodations may be required should contact Professional and Scientific Associates at (703) 234-1700 and reference this meeting. Requests for special accommodations should be made at least ten (10) business days prior to the meeting.

Members of the public will have an opportunity to provide comments at the meeting. Public comments will be limited to two minutes per speaker during the time allotted. Individuals who would like to submit written statements should email, mail, or fax their comments to the designated contact at least seven (7) business days prior to the meeting.

Any members of the public who wish to have electronic or printed material distributed to ACMH members should email [OMH-ACMH@hhs.gov](mailto:OMH-ACMH@hhs.gov) or mail their materials to the Designated Federal Officer, ACMH, Tower Building, 1101 Wootton Parkway, Suite 600, Rockville, Maryland 20852, prior to close of business on June 14, 2018.

Dated: May 4, 2018.

**Minh Wendt,**

*Designated Federal Officer, Advisory Committee on Minority Health.*

[FR Doc. 2018-10125 Filed 5-10-18; 8:45 am]

**BILLING CODE 4150-29-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of General Medical Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* NIGMS Initial Review Group; Training and Workforce Development Subcommittee—B Review of T32 Applications.

*Date:* June 25–26, 2018.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at Chevy Chase, 4300 Military Road NW, Washington, DC 20015.

*Contact Person:* Lisa A. Newman, SCD, Scientific Review Officer, Office of Scientific Review, National Institutes of General Medical Sciences, 45 Center Drive, RM 3AN18A, Bethesda, MD 20814, (301) 435-0965, [newmanla2@mail.nih.gov](mailto:newmanla2@mail.nih.gov).

*Name of Committee:* NIGMS Initial Review Group; Training and Workforce Development Subcommittee—A Review of T32 Applications.

*Date:* July 16–17, 2018.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at Chevy Chase, 4300 Military Road NW, Washington, DC 20015.

*Contact Person:* John J. Laffan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18J, Bethesda, MD 20892, 301-594-2773, [laffanjo@mail.nih.gov](mailto:laffanjo@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: May 8, 2018.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2018-10078 Filed 5-10-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Draft Report on Carcinogens Monograph on *Helicobacter pylori*: Chronic Infection; Availability of Document; Request for Comments

**AGENCY:** National Institutes of Health, HHS

**ACTION:** Notice.

**SUMMARY:** The National Toxicology Program (NTP) announces the availability of the Draft Report on Carcinogens (RoC) Monograph on *Helicobacter pylori*: Chronic Infection

for public comment. The Office of the Report on Carcinogens (ORoC), Division of the National Toxicology Program (DNTP), National Institute of Environmental Health Sciences (NIEHS) prepared the monograph.

**DATES:**

*Document Availability:* The draft monograph should be available by May 11, 2018, at <https://ntp.niehs.nih.gov/go/845046>.

*Written Public Comments*

*Submission:* Deadline is June 1, 2018.

**ADDRESSES:** Written public comments should be submitted electronically at <https://ntp.niehs.nih.gov/go/845046>.

**FOR FURTHER INFORMATION CONTACT:** NTP Meetings Staff, 2635 Meridian Parkway, Suite 200, Durham, NC, USA 27713. Phone: (919) 293-1660, Fax: (919) 293-1645, Email: [NTP-Meetings@icf.com](mailto:NTP-Meetings@icf.com).

**SUPPLEMENTARY INFORMATION:**

*Background:* The RoC is a congressionally mandated, science-based, public health report that identifies agents, substances, mixtures, or exposures (collectively called "substances") in our environment that pose a cancer hazard for people in the United States. NTP prepares the RoC on behalf of the Secretary of Health and Human Services.

NTP follows a four-part process using established listing criteria to evaluate substances for possible listing in the RoC and prepare the report (<https://ntp.niehs.nih.gov/go/rocprocess>). For each substance selected for review, a draft RoC monograph is prepared that presents (1) information on human exposure to the substance; (2) an assessment of the evidence from cancer studies in humans and experimental animals, mechanisms of carcinogenicity, and other data relevant for evaluating the substance's potential carcinogenicity; and (3) NTP's preliminary RoC listing recommendation. This information is presented in the substance profile in the *Helicobacter pylori* (*H. pylori*) monograph. The monograph also includes a summary of strategies to prevent *H. pylori*-associated cancers.

*H. pylori* was selected for review following solicitation of public comment, review by the NTP Board of Scientific Counselors on April 11, 2016, and approval by the NTP Director (<https://ntp.niehs.nih.gov/go/9741>). Information on the NTP review of *H. pylori* is available at <https://ntp.niehs.nih.gov/go/791433>. *H. pylori*

is a gram-negative, multi-flagellated bacterium that colonizes the luminal mucosal surface of the body (corpus) and lower portion (antrum) of the stomach; if untreated, the infection

usually lasts for the individual's lifetime. Chronic infection can cause gastritis and peptic ulcers. The bacterium is spread by person-to-person contact, especially among family members. Risk factors for *H. pylori* infection include age, race or ethnicity (minority), socioeconomic status (low family income and lower education level), and crowded housing.

*Request for Comments:* NTP invites written public comments on the draft monograph. The deadline for submission of written comments is June 1, 2018. Written public comments should be submitted electronically at <https://ntp.niehs.nih.gov/go/845046>. Any other correspondence should be sent to NTP Meetings Staff by email: [NTP-Meetings@icf.com](mailto:NTP-Meetings@icf.com). Persons submitting written comments should include their name, affiliation (if applicable), phone, email, and sponsoring organization (if any) with the document. Written comments received in response to this notice will be posted on the NTP website (<https://ntp.niehs.nih.gov/go/845046>), with the submitter identified by name, affiliation, and/or sponsoring organization. Following the public comment period, the draft monograph will undergo external peer review by letter. Comments that address scientific or technical issues will be shared with external scientists for their consideration during the peer review. Guidelines for public comments are at [http://ntp.niehs.nih.gov/ntp/about\\_ntp/guidelines\\_publiccomments\\_508.pdf](http://ntp.niehs.nih.gov/ntp/about_ntp/guidelines_publiccomments_508.pdf).

*Background Information on RoC:* Each edition of the RoC is cumulative and consists of substances newly reviewed in addition to those listed in previous editions. The Secretary of Health and Human Services approves new listings. For each listed substance, the RoC contains a substance profile, which provides information on cancer studies that support the listing—including those in humans and animals and studies on possible mechanisms of action, informational about potential sources of exposure to humans, and current Federal regulations to limit exposures. The 14th RoC, the latest edition, was published on November 3, 2016 (available at <http://ntp.niehs.nih.gov/go/roc>).

Dated: May 2, 2018.

**Brian R. Berridge,**

*Associate Director, National Toxicology Program.*

[FR Doc. 2018-10075 Filed 5-10-18; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Institute of Mental Health; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis.

*Date:* June 5, 2018.

*Time:* 12:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

*Contact Person:* Vinod Charles, Ph.D., Scientific Review Officer Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892-9606, 301-443-1606, [charlesvi@mail.nih.gov](mailto:charlesvi@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders.

*Date:* June 7, 2018.

*Time:* 12:30 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Marcy Ellen Burstein, Ph.D., Scientific Review Officer Division of Extramural Activities, National Institute of Mental Health, NIH Neuroscience Center, 6001 Executive Blvd., Room 6143, MSC 9606, Bethesda, MD 20892-9606, 301-443-9699, [bursteinme@mail.nih.gov](mailto:bursteinme@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; Early Phase Developmental Pharma/Device Clinical Trials.

*Date:* June 12, 2018.

*Time:* 11:30 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health Neuroscience Center, 6001 Executive